Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN: Daratumumab and Belatacept for Highly Sensitized Kidney Transplant Candidates
NCT04827979Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2021
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, belatacept in sensitization in kidney transplantation (PRA), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2021; status: completed.
02
Drugs
daratumumabbelatacept
03
Conditions
sensitization in kidney transplantation (PRA)
Beyond the preview
Go deeper on NCT04827979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827979.